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Abstract  
The application of time-resolved fluorescence sensing to the study of heterogenic 
biomolecular systems remains challenging due to the complexity of the resulting 
photophysics. Measuring the time-resolved emission spectra (TRES) can provide a more 
informative alternative to the modelling of the fluorescence decay that is currently employed. 
Here we demonstrate this approach by monitoring real-time changes in intrinsic insulin 
fluorescence by TRES as a straightforward probe to directly measure kinetics of insulin 
aggregation and glycation. Our findings hold promise for monitoring the storage of insulin 
and its application in the control of diabetes, and may support the development of more 
effective therapeutics against amyloidosis. 
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1.  Introduction  
 
Protein aggregation has been intensively studied over the past decades due to its role in  
neurodegenerative diseases including Alzheimer’s, Parkinson’s and diabetes mellitus.1,2 The 
process results from the misfolding of otherwise normally functional soluble proteins, leading 
to the formation of amyloid fibrils and eventually insoluble amyloid deposits in the brain of 
patients.  
Insulin is a hormonal protein which stabilizes blood glucose levels, when produced in the 
pancreas. It is stored as medicine in its most stable hexameric form.3 However, insulin 
aggregation still occurs in its stabilized form, which becomes problematic for long term 
storage. Insulin fibrils formed as the result of aggregation are found to be cytotoxic4 and 
cause localized amyloidosis at frequent injection sites.5 Moreover, insulin oligomers and 
fibrils cause an autoimmune response in serum from patients with Parkinson’s disease.6 
Despite insulin aggregation occurring under physiological conditions, a great deal of studies 
were conducted under non-physiological conditions such as acidic pH and high temperatures, 
which accelerate fibril formation.7–9 
Insulin is associated with glycaemia but reducing sugars are known to interact and modify 
proteins through a non-enzymatic reaction known as glycation. Glycation occurs when the 
carbonyl group of the sugar and a free amino group (typically from arginine and lysine 
residues, or N-terminal amino group) forms a Schiff’s base.10 Amadori products are produced 
when the Schiff base rearranges itself into a stable ketoamine. Dehydration reactions and 
further rearrangements generate advanced glycation end products (AGEs) and play a role in 
diabetes and cataracts. Glycated proteins are found in Lewy bodies11 and 𝛽-amyloid (A𝛽)12 
deposits which are related to Parkinson’s disease and Alzheimer’s disease, respectively. 
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Therefore, it is thought that reducing sugars could induce protein aggregation and misfolding, 
and the formation of cross-links with protein which increases the stability of protein 
aggregates13. Glycated insulin is unable to transport glucose to cells and inhibits the 
regulation of blood glucose, therefore, reducing sugars play a key role in insulin 
resistance14,15. 
The insulin monomer consists of two polypeptide chains, named A and B. Chain A has 21 
amino acids and B has 30 amino acids, both chains are linked together by two disulphide 
bridges. Together they contain seven intrinsic fluorophores: four tyrosine (Tyr) and three 
phenylalanine (Phe) residues. However, the hexameric insulin form produced and stored in 
the pancreas consists of three dimers stabilized by zinc ions. Using mass spectrometry, 
glucose binding sites have been found Lys (B29) in chain B and in the N-terminus of both 
chains A and B16,17. From nuclear magnetic resonance nuclear Overhauser effect 
spectroscopy (NMR NOESY) experiments it was found that Val (B2) and Leu (B17) were the 
best residues for glucose interaction18 and molecular dynamics (MD) simulations showed that 
glucose had a large affinity towards the hydrophobic pocket between Val (B2) and Leu 
(B17)19. It has been reported that free insulin in non-reducing conditions has the tendency to 
form oligomers, whereas oligomerization in glycated insulin is low20, therefore glucose 
inhibits amyloid formation21. Although significant glycation occurs over a number of 
weeks22, insulin glycation is measured in non-physiological conditions spanning only over a 
few hours or days.   
In our previous study23, we have explored the sensitivity of the intrinsic tyrosine fluorescence 
to study insulin alterations and recovered the kinetics of its aggregation with the use of time-
resolved emission spectra (TRES). It has been found that hexameric insulin under 
physiological conditions undergoes conformational changes throughout 700 hours. This was 
further supported by similar assembly kinetics of a model fibrillar protein24 suggesting a 
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generic mechanism and that the sufficient sensitivity of TERS to monitor protein stability for 
medicinal purposes. 
In this present study, we demonstrate the medical application of this methodology and 
compare evolution of TRES of free insulin and glycated insulin. As there are no tryptophan 
(Trp) residues in insulin, the fluorescence kinetics are simplified. Understanding this kinetics 
is likely to provide insights into the mechanism of insulin glycation which, in turn, may 
enable the development of better therapeutics to halt or circumvent fibril formation. 
 
2. Methods 
Bovine insulin, D-(+)-Glucose, and phosphate-buffered saline pH 7.4 (PBS) from Sigma-
Aldrich were used without further purification. Two 50 μM bovine insulin samples were 
prepared in PBS buffer (0.01 M). A stock solution of D-(+)-Glucose in distilled water was 
added to one bovine insulin sample and the final concentration of glucose was 50 mM. The 
samples were sonicated, stored, and measured at 22⁰C. The absorption and fluorescence 
steady state spectra were measured with the use of Lambda 25 UV-Vis spectrometer (Perkin-
Elmer) and Fluorolog (Horiba Scientific), respectively. A series of time-resolved 
fluorescence decays were measured on a DeltaFlex fluorescence lifetime system (Horiba 
Jobin Yvon IBH Ltd, Glasgow) with the use of time correlated single photon counting 
(TCSPC) technique. To excite intrinsic tyrosine fluorescence within the sample, a 279 nm 
NanoLED was used25. In order to retrieve sufficient amount of data for TRES calculations, 
the fluorescence decay detection wavelengths  ranged from 290-350 nm at 5 nm intervals. 
Polarization effects are limited within the fluorescence decay by setting the polarizer in the 
detection channel at the magic angle (54.7⁰) in respect to vertically-oriented polarizer in the 
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excitation channel. The series of fluorescence decays for a range of wavelengths were fitted 
to a 3-exponential function.  
𝐼𝜆(𝑡) =  ∑ 𝛼𝑖(𝜆) exp (
−𝑡
𝜏𝑖(𝜆)
) 
3
𝑖=1
 
 
(1) 
 
where 𝜏𝑖(𝜆) and 𝛼𝑖(𝜆) are the fluorescent lifetimes and pre-exponential factors with respect 
to each detection wavelength, respectively. The goodness of fit criteria were examined with 
the use of the nonlinear least squares method. The weighted residuals and χ2 indicated that a 
3-exponential function described the fluorescence decay adequately.  
The recovered parameters 𝜏𝑖(𝜆) and 𝛼𝑖(𝜆) were then used to generate TRES 𝐼𝑡(𝜆): 
 
𝐼𝑡(𝜆) =  ∑
𝐼𝜆(𝑡) 𝑆(𝜆) 
∑ 𝛼𝑖(𝜆)𝜏𝑖()𝑖
3
𝑖=1
 
(2) 
 
  
where 𝑆(𝜆) is the steady state spectrum of the sample. Experimental TRES have been 
converted to the wavenumber scale according to  
 𝐼𝑡(𝑣) = 𝜆
2𝐼𝑡(𝜆) (3) 
 
and modelled in terms of the multiple normalised Toptygin-type distributions26 which 
represent the spectral shapes of individual fluorescence components within the superimposed 
TRES.  
𝐹(𝑣) = ∑
𝐶𝑖 
√2𝜋 𝑣𝑖𝜎𝑖(𝑣𝑖
2 + 3𝜎𝑖
2)
𝑣3 𝑒𝑥𝑝 (
−(𝑣 − 𝑣𝑖)
2
2𝜎𝑖
2 )
𝑁
𝑖=1
                    (4) 
where 𝐶𝑖 , 𝜈𝑖 and 𝜎𝑖 is the fluorescence contribution, peak position, and half-width of the 
distribution of each component, respectively. The expression (√2𝜋 𝑣𝑖𝜎𝑖(𝑣𝑖
2 + 3𝜎𝑖
2))
−1
 is the 
normalised factor for each spectrum component.  The Toptygin-type model (4) parameters 
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were recovered by fitting the distributions 𝑣−3𝐹() to the experimental TRES expressions of 
𝑣−3𝐼𝑡(𝜈).  
 
3. Results and discussion 
The steady state emission spectra for free insulin (figure 1A) shows that from 0.5 to 310 
hours of incubation time the fluorescence intensity decreases but the shape of the spectra is 
maintained. The decrease in tyrosine fluorescence intensity was also observed by Bekard et 
al.27 and there was an increase in the 1-anilinonaphthalene-8-sul- phonic acid (ANS) signal 
measured in a 22 hour time range. Tyrosine residues (A14), (B16) and (B26) are located on 
hydrophobic surfaces within insulin28 and ANS is a probe commonly used to bind in 
hydrophobic regions. Therefore, the decrease in intensity may be due to the conformational 
changes which expose tyrosine residues to quenchers in the solution. After about 310 hours, 
the spectra experience a further decrease and broaden quite significantly. The normalised 
spectra (figure 1B) demonstrate large broadening with a new peak emerging around 330 nm. 
These effects are likely to be a result of formation of aggregates in a distribution of 
conformations which fluorescent at longer wavelengths.  
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Figure 1: Fluorescence intensity of free insulin A) at 0.5, 26, 44, 196, 310, 
379, 459, 528, 605, 692 hours of preparation and insulin with glucose C) 
measured at 0.1, 30, 53, 72, 192, 318, 384, 479, 527, 577, 655 and 699 hours 
after preparation. The corresponding normalised intensities are shown in B) 
and D) respectively. 
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In case of when insulin was incubated with glucose the fluorescence intensity (shown in 
figure 1C) decreased at a time range of 0.1 to 30 hours and then starts to increase. For the 
first 30 hours the trend appeared to be similar to that of free insulin but it started at a lower 
level, which may be due to glucose quenching the overall tyrosine fluorescence. At later 
times glucose inhibits quenching of tyrosine which may be caused by glucose acting as a 
shield around insulin and tyrosine is no longer exposed to the water, which in turn, increases 
tyrosine fluorescence. The normalised spectra shown on figure 1D also shows that the spectra 
starts to broaden after 192 hours and there is a second peak around 330 nm, which is not as 
prominent as in free insulin.  
The readings of the fluorescence peak intensities were taken at 298 nm for both free insulin 
and insulin with glucose and were plotted on figure 2A. The total fluorescence intensities 
were also calculated by taking the integral of the fluorescence spectrum of each measured 
sample (figure 2B). The peak intensity for free insulin decreases but the integrated 
fluorescence intensity remains constant. This is consistent with formation of aggregates of 
different sizes, each showing varied peak positions on the spectrum.  
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Figure 2: A) Peak fluorescence intensity at 298 nm and B) 
integrated fluorescence spectra taken from 50 μM insulin (◼) in 
PBS buffer and 50 μM insulin with 50 mM (Ο) glucose in PBS 
buffer. 
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For glycated insulin, both the peak intensity and total number of photons emitted increase, 
which, in turn, suggests not only formation of aggregates (broadening the spectra), but also 
sugar molecules separating Tyr from the solvent (which increases quantum yield, thus also 
fluorescence intensity).   
The fluorescence decays for free and glycated insulin were measured at several times over the 
period of about 700 hours of incubation. The emission wavelength detection ranged from 290 
– 350 nm in increments of 5 nm. It can be observed (Fig.3) that increasing incubation time of 
both samples results in longer lifetimes and the spread of the decays are more significant in 
the free insulin sample. This may indicate that the glucose-insulin complexation makes 
tyrosine local environments less heterogenic. 
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Figure 4 shows examples of TRES of the free insulin and glycated insulin samples after 0.35, 
194 and 690 hours of incubation.  At 0.35 hours (Fig.4.A and B), the fluorescence intensity of 
free insulin is lower as compared with the insulin with glucose, but the normalised TRES 
plots show similar trends. The increased intensity in the sample with glucose is consistent 
with the steady-state data and may be explained by glucose shielding insulin from water 
Figure 3: Raw fluorescence decays of free insulin measured at A) 
0.35 and B) 690 hours and insulin with glucose measured at C) 5 and 
D) 693 hours after sample preparation. 
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molecules that would normally quench tyrosine fluorescence.  After 194 hours (Fig.4.C and 
D), glucose influence on tyrosine fluorescence is substantially different: the intensity, as 
compared to free insulin, decreases faster at higher wavenumbers and slower at smaller 
wavenumbers.  This may be explained in terms of the variety of possible complexes between  
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non-glycated, non-glycated/glycated, and glycated only insulin molecules, which results in 
much broader range of local environments for tyrosine, thus broadening the fluorescence 
spectrum. During the initial ~300 hours we can observe the two dominating bands in the 
TRES, one at ~32500 cm-1, which is the tyrosine fluorescence in glycated insulin, slightly 
shifted towards lower energies (as compared to free insulin) due to sugar binding, and the 
other one around ~30000 cm-1, which is likely to be fluorescence of the insulin glycation 
Figure 4: TRES of free insulin (black curves) and 
insulin with glucose (grey curves). The left hand panel 
demonstrates the evolution of time 0, 0.25, 0.5, 0.75, 1, 
1.5, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ns after excitation. 
Samples were measured at times 0.35 (A), 194 (C), and 
690 (E) hours. The right hand panel illustrates 
normalised TRES.  
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products. Their intensity decays are slower than these of the non-complexed molecules, 
because the TRES peak at 30000 cm-1 decreases slower than the one at 32500 cm-1.   
For the glycated sample incubated for longer than 350 hours (see Supporting Information), 
the fluorescence peak of the complexes shifts towards higher energies and the rate of its 
decay becomes faster and at times 500-700 hours the TRES almost does not change its shape. 
At the moment we explain this by glycated insulin aggregates binding together to form 
fibrils/AGEs, which are more rigid than smaller aggregates. This results in limited 
orientational freedom for tyrosines (more stable TRES) and quenching by tightly packed 
complexes (shorter lifetimes).  
For quantitative interpretation of the TRES results, the 2-component spectrum model (Eqtn 4) 
was fitted to the TRES spectra of both samples and its parameters were recovered. The 
positions of spectral peaks i(t) are plotted in figure 5.  
                                   
28
29
30
31
32
33
34
0 2 4 6 8 10 0 2 4 6 8 10
28
29
30
31
32
33
34

i /
 1
0
3
 c
m
-1
t / ns
1 0.35 - 690 h
2
0.35 - 196 h
379 - 690 h

i /
 1
0
3
 c
m
-1
t / ns
310 h
1 0.35 - 690 h
2
0.35 - 196 h
379 - 690 h
B)A)
 
                  
 
 
The higher energy peaks 1(t) occur for both samples around 33,000 cm-1 and remain stable 
throughout the measured 700 hours.  The changes in the second peaks positions2(t) depend 
substantially on the incubation times of the samples. During the first 200 hours 2(t) for both 
samples decrease from ~32,000 cm-1  to ~30,000 cm-1 during 10 ns after excitation, however 
Figure 5: Gaussian models were used to fit TRES spectra for 
A) free insulin and B) insulin with glucose and the peak 
positions 𝜈𝑖 were extracted and plotted for 0.33 (◼), 22 (⚫), 42 
(◄), 68 (▲), 93 (▼), 196 (◆), 310 (►) 379 (★), 458 (⬟), 
528 (◕), 605 (|), and 690 (╳) hours. The components 1 and 2 are 
represented with grey and red symbols, respectively. 
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there is a substantial difference between the free and glycated insulin. While the 2(t) in a free 
insulin sample has a decreasing trend in all stages of aging, 2(t) in the glycated sample 
seems to increase over the first two nanoseconds after excitation. We think this is due to the 
presence of a third fluorescent glycation product not appearing in a free insulin sample. Its 
presence increases the complexity of the fluorescence spectrum and the two-component 
model is no longer adequate, thus the apparent increase in 2(t) in the way the model 
accommodates the additional fluorescence.  
In older samples, aged 379 to 690 hours of incubation, 2 values start at lower level of 
~30,500 cm-1 which is probably caused by tighter aggregation of insulin proteins. The free 
insulin sample (red curves) still show a red-shift of 2 to about 29500 cm-1, while the glycated 
sample (green curves) shows only slight shifts, confirming formation of more rigid structures. 
 
4. Conclusions 
To summarise, we suggest that observed modifications of TRES offer the opportunity to 
distinguish between different forms of protein glycation, thus offering systematic studies of 
glycation induced by variety of sugars, environmental conditions, anti-glycation factors, etc. 
However, this aim cannot be achieved by fitting experimental TRES to the more complex 
models of the spectrum, as this approach is already the subject of several assumptions (a 3-
exponential representation of the individual fluorescence intensity decays, Toptygin-type 
profile of the spectrum). Instead, the experimental TRES could be considered as an 
approximation and used to propose a selection of alternative models of the kinetics, for which 
the relevant fluorescence intensity decays I(t) will be calculated numerically. Confirmation 
of the specific type of glycation would be achieved of the basis of finding the best-fitting 
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kinetic model and the values of its parameters. Our preliminary attempts to fit the numerical 
solutions of the kinetic models to the experimental decay data demonstrate full feasibility of 
this approach. 
 
Associated content 
Supporting Information: TRES of free insulin and insulin with glucose over ~700 h, 
parameters of Gaussian models fitted to TRES.  
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Figure S1: TRES of free insulin (black curves) and insulin with glucose (red curves). The left hand 
panel demonstrates the evolution of time 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ns after 
excitation. Samples were measured at times A) 0.35, C) 22, E) 42, G) 68, I) 93, K) 196, M) 310, O) 
379, Q) 458, S) 528, U) 605 and W) 690 hours. The right hand panel illustrates normalised TRES. 
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Figure S1-cont’d: TRES of free insulin (black curves) and insulin with glucose (red curves). The left 
hand panel demonstrates the evolution of time 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ns 
after excitation. Samples were measured at times A) 0.35, C) 22, E) 42, G) 68, I) 93, K) 196, M) 310, 
O) 379, Q) 458, S) 528, U) 605 and W) 690 hours. The right hand panel illustrates normalised TRES. 
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Figure S1-cont’d: TRES of free insulin (black curves) and insulin with glucose (red curves). The left 
hand panel demonstrates the evolution of time 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ns 
after excitation. Samples were measured at times A) 0.35, C) 22, E) 42, G) 68, I) 93, K) 196, M) 310, 
O) 379, Q) 458, S) 528, U) 605 and W) 690 hours. The right hand panel illustrates normalised TRES. 
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Figure S1-cont’d: TRES of free insulin (black curves) and insulin with glucose (red curves). The left 
hand panel demonstrates the evolution of time 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, and 10 ns 
after excitation. Samples were measured at times A) 0.35, C) 22, E) 42, G) 68, I) 93, K) 196, M) 310, 
O) 379, Q) 458, S) 528, U) 605 and W) 690 hours. The right hand panel illustrates normalised TRES. 
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Figure S2: Gaussian models were used to fit TRES spectra for free insulin and insulin with glucose 
and the peak positions 𝝂𝒊 were extracted and plotted for 0.33 (◼), 22 (⚫), 42 (◄), 68 (▲), 93 (▼), 
196 (◆), 310 (►) 379 (★), 458 (⬟), 528 (◕), 605 (|), and 690 (╳) hours. Component 1 and 2 for free 
insulin and insulin with glucose are represented with grey, red, blue, and green, respectively. 
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Figure S3: Gaussian models were used to fit TRES spectra for free insulin and insulin with glucose 
and the peak positions 𝐶𝒊 were extracted and plotted for 0.33 (◼), 22 (⚫), 42 (◄), 68 (▲), 93 (▼), 
196 (◆), 310 (►) 379 (★), 458 (⬟), 528 (◕), 605 (|), and 690 (╳) hours. Component 1 and 2 for free 
insulin and insulin with glucose are represented with grey, red, blue, and green, respectively. 
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Figure S4: Gaussian models were used to fit TRES spectra for free insulin and insulin with glucose 
and the peak positions 𝑪𝒊 were extracted and plotted  in log scale for 0.33 (◼), 22 (⚫), 42 (◄), 68 
(▲), 93 (▼), 196 (◆), 310 (►) 379 (★), 458 (⬟), 528 (◕), 605 (|), and 690 (╳) hours. Component 1 
and 2 for free insulin and insulin with glucose are represented with grey, red, blue, and green, 
respectively. 
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Figure S5: Gaussian models were used to fit TRES spectra for A) free insulin and B) insulin with 
glucose and the peak positions 𝐶𝒊 were extracted and plotted for 0.33 (◼), 22 (⚫), 42 (◄), 68 (▲), 93 
(▼), 196 (◆), 310 (►) 379 (★), 458 (⬟), 528 (◕), 605 (|), and 690 (╳) hours. Components 1 and 2 are 
represented with grey and red curves, respectively. 
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Figure S6: Gaussian models were used to fit TRES spectra for free insulin and insulin with glucose 
and the peak positions 𝝈𝒊 were extracted and plotted for 0.33 (◼), 22 (⚫), 42 (◄), 68 (▲), 93 (▼), 
196 (◆), 310 (►) 379 (★), 458 (⬟), 528 (◕), 605 (|), and 690 (╳) hours. Component 1 and 2 for free 
insulin and insulin with glucose are represented with grey, red, blue, and green, respectively. 
 
